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Abstract
Background: The antibody response to HIV-1 does not appear in the plasma until approximately 2–5 weeks after
transmission, and neutralizing antibodies to autologous HIV-1 generally do not become detectable until 12 weeks or more
after transmission. Moreover, levels of HIV-1–specific antibodies decline on antiretroviral treatment. The mechanisms of this
delay in the appearance of anti-HIV-1 antibodies and of their subsequent rapid decline are not known. While the effect of
HIV-1 on depletion of gut CD4
+ T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon
after infection to determine the effect of early HIV-1 on these cells.
Methods and Findings: In human participants, we analyzed B cells in blood as early as 17 days after HIV-1 infection, and in
terminal ileum inductive and effector microenvironments beginning at 47 days after infection. We found that HIV-1
infection rapidly induced polyclonal activation and terminal differentiation of B cells in blood and in gut-associated
lymphoid tissue (GALT) B cells. The specificities of antibodies produced by GALT memory B cells in acute HIV-1 infection
(AHI) included not only HIV-1–specific antibodies, but also influenza-specific and autoreactive antibodies, indicating very
early onset of HIV-1–induced polyclonal B cell activation. Follicular damage or germinal center loss in terminal ileum Peyer’s
patches was seen with 88% of follicles exhibiting B or T cell apoptosis and follicular lysis.
Conclusions: Early induction of polyclonal B cell differentiation, coupled with follicular damage and germinal center loss
soon after HIV-1 infection, may explain both the high rate of decline in HIV-1–induced antibody responses and the delay in
plasma antibody responses to HIV-1.
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Early HIV-1 infection is characterized by the death of both
infected and uninfected CD4
+ T cells, often resulting in extensive
CD4
+ T cell depletion in the gastrointestinal tract [1–6]. While
HIV-1 induction of CD4
+ T cell death in early infection is well
documented, the effects of HIV-1 on blood and mucosal B cells
and their inductive microenvironments in the earliest stages of
infection have not been determined. In chronic infection, HIV-1
induces polyclonal B-cell activation, B cell exhaustion, hypergam-
maglobulinemia, reductions in the numbers of memory B cells in
the blood, and increased numbers of circulating immature B cells
[7–12]. People with early HIV-1 infection have elevated
frequencies of blood antibody-secreting cells that may reflect
Env-mediated polyclonal activation [10,13,14], but have been
reported to have normal numbers of blood naı ¨ve and memory B
cells [15].
Priming immunizations of healthy humans with nonpathogenic
non-HIV-1 viruses elicit detectable neutralizing antibody within a
few days of priming, with peak neutralization titers observed on
day 14 [16,17]. In contrast, the earliest B cell responses to HIV-1
are not detected until ,19 d after transmission in the form of
antibody–virion immune complexes, and ,2–5 wk after trans-
mission in the form of HIV-1 antibodies in plasma [18]. Most
importantly, functionally relevant neutralizing antibodies against
autologous virus do not generally appear in plasma until $12 wk
after HIV-1 infection [19–21]. Moreover, antiretroviral therapy in
chronic HIV-1 infection is associated with an increased rate of
decline of plasma antibodies resulting in an apparent half-life of
anti-HIV-1 gp120 antibody of 7–21 wk, and for anti-p24 antibody
of 9–15 wk [14]. The mechanisms of delay in the appearance of
anti-HIV-1 antibodies after HIV-1 transmission and of the rapid
decline of induced anti-HIV-1 antibodies are not known.
Given the potential capacity of neutralizing serum antibody to
prevent HIV-1 infection, as demonstrated by passive transfer of
protective antibody to rhesus macaques challenged with simian
human immunodeficiency virus [22,23], it is critical to define the
early effects of HIV-1 infection on B cells and on their inductive
and effector mucosal microenvironments. Detailed examination of
how HIV-1 subverts initial humoral responses will determine how
quickly vaccine-primed neutralizing antibodies must appear in
order to be effective. In this study, we investigated the effects of
acute and early HIV-1 infection on naı ¨ve B cells, memory B cells,
and plasma cells in blood, Peyer’s patches, and lamina propria.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Duke University Medical Center,
the University of North Carolina Medical Center, the University
of Alabama Birmingham, and the Aaron Diamond AIDS
Research Center. All patients provided written informed consent
for the collection of samples and subsequent analysis.
Study Participants
Patients were recruited for terminal ileum (Table 1) and blood
samples (Table 2) under IRB-approved protocols for CHAVI 001
and CHAVI 012 studies of acute HIV-1 infection. Control
samples of blood were obtained from healthy uninfected
volunteers; control samples for terminal ileum biopsies were
obtained from healthy uninfected volunteers or as de-identified
and discarded tissue samples from the Duke Surgical Pathology
Department from patients undergoing surgery for colon cancer,
colon polyps, or endometriosis. Differences between HIV-1
infected patients who were on or off antiretroviral treatment
(ART) were not statistically significant (t-test) for age, time from
transmission, or cell counts (CD3
+, CD4
+, CD8
+) for both those
contributing terminal ileum biopsies and those contributing
peripheral blood (Tables 1 and 2). For viral load (VL) data, tests
were performed on the natural logarithm of VL and were not
statistically significant (t-test) between the on- and off-ART groups
except for plasma VL for participants contributing peripheral
blood (p=0.035, t-test). Time from transmission was precisely
known in many patients by history, and was inferred clinically in
others from their last high-risk behavior prior to documented
infection. Many participants came from the CHAVI 001 acute
HIV-1 infection protocol that detects plasma VL-positive, serum
antibody–negative AHI patients by VL screening. The patients
studied were classified as having either early acute HIV-1 infection
(#40 d after transmission) or early HIV infection (41–200 d after
transmission) (Tables 1 and 2). In this study all patients were
within the first 200 d of infection and are analyzed together as
‘‘acute,’’ although those who donated after day 40 from
transmission are only early in infection. In the CHAVI 012
protocol, participants were asked to donate terminal ileum biopsies
and paired blood samples. Six of the 14 patients who donated
terminal ileum samples elected not to donate paired blood samples
and thus were not included in the blood B cell analysis presented
in Table 2. There was no obvious source of selection bias noted for
the groups in Tables 1 and 2.
Flow Cytometry Analysis of Terminal Ileum and Blood B
Cells
Terminal ileum mononuclear cells were isolated from gut tissues
followed by Ficoll-Hypaque density gradient centrifugation and
were not further enriched prior to antibody staining. Peripheral
blood B cells were enriched before antibody staining using
RosetteSep B-cell enrichment cocktail (STEMCELL Technolo-
gies). A panel of monoclonal antibodies was used to identify
distinct human B cell subsets in various tissues using nine-color
flow cytometry on a BD FACSAria (BD Biosciences). B cells were
defined as CD3
2/CD14
2/CD16
2/CD235a
2 and CD19
+. B cell
subsets were defined as follows: naı ¨ve B cells as IgD
+, IgM
+,
CD27
2; memory B cells as IgD
2, CD38
2/+, CD27
+; plasma-
blasts/plasma cells as IgD
2, CD38
hi, CD27
+ (Text S1) [24,25].
Combinations of the following antibodies were used: IgM (FITC),
IgD (PE), CD3 (PE-Cy5), CD4 (PE-Cy7), CD5 (PE-Cy7), CD8
(APC), CD14 (PE, PE-Cy5), CD16 (FITC, PE-Cy5), CD19 (APC-
Cy7), CD20 (PE-Cy7), CD27 (PacificBlue), CD56 (PE-Cy5),
CD235a (PE-Cy5) from BD Biosciences; CD3 (APC-Cy5.5),
CD14 (PE-Cy5), CD38 (APC-Cy5.5 or AlexaFluor 700), CD45
(PacificBlue) from Caltag/Invitrogen; CD38 (APC-Cy5.5 or
AlexaFluor 700) from eBioscience.
Immunohistologic and Quantitative Image Analysis of
Terminal Ileum Tissue Immune Cells
Formalin-fixed biopsies of terminal ileum were cut into 5 mm
thick sections, treated for antigen retrieval when required using
standard techniques [26], and stained with saturating amounts of
the monoclonal or polyclonal antibodies against: CD3, CD4,
CD8, CD57, CD16, Langerin, CD83, CD11c, CD56, CD68,
CD20, IgG, IgM, IgA, kappa and lambda light chains, CD21,
CD35, and nerve growth factor receptor p75. Secondary stains
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against the species of the primary antibody followed by
development with 3,3-diaminobenzidine in the presence of
hydrogen peroxide. Some slides were prepared with TUNEL
stains for apoptotic cells using standard techniques (see Table S1
for antibody sources).
For quantitative image analysis, the area in cubic millimeters of
a4 0 6field was evaluated using an LCD monitor and a Nikon D5-
Fi1 camera with the NIS Elements F3 program. Five 406 fields
were photographed and the average number of lamina propria
cells per field that stained positive for the monoclonal antibody
were counted [27]. The number of cells/mm
3 of tissue was
calculated by the equation:
Cells=mm3~
Average number of cells
0:005 mm thickness of the tissue|the area of the 40| field 0:0719 mm2 ðÞ :
Peyer’s patch germinal centers were identified by a combination
of morphology in hematoxylin and eosin stains, the presence of Ki-
67
+ dividing germinal center cells, and identification of follicular
dendritic cells (FDCs). FDCs were identified by reactivity with
CD21, CD35, or anti-nerve growth factor receptor p75 monoclo-
nal antibodies [23], and similar results were found using each
reagent. Follicular damage and loss of germinal centers (follicular
lysis) was determined by TUNEL stains for apoptotic cells in T
and B cell areas, CD8
+ T cell and macrophage infiltration of
follicles, visible damage to follicles visible by hematoxylin and
eosin staining, loss of Ki-67
+ (dividing) germinal center cells, and
loss of the normal fine reticular pattern of FDCs. In some sections
apoptotic bodies outside of tingible body macrophages could be
seen within germinal centers on hematoxylin and eosin-stained
sections.
Epstein-Barr Virus B Cell Transformation and Assays for
Antibody Specificity
Mucosal cells isolated from terminal ileal samples of participants
were transformed with Epstein-Barr virus (EBV) to generate B-
lymphoblastoid cell lines according to the methods described
previously [28]. Briefly, the cells were resuspended in culture
medium (RPMI supplemented with 15% heat-inactivated fetal calf
serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, and
50 mg/ml of gentamicin) and incubated with an EBV suspension
(from B95-8 B cell line) in the presence of phytohemagglutinin
(2 mg/ml; Sigma). After 4 h, cells were plated at 10
4 cells per well
in 96-well plates (round bottom).
Three to four weeks after plating, levels of total IgA, IgG, and
IgM in the supernatants were determined by ELISA. Briefly, 96-
well plates (Costar) were coated with 5 mg/ml of goat anti-human
immunoglobulins (Invitrogen) in 0.1 M sodium bicarbonate
buffer. After incubating overnight at 4uC, plates were blocked
with PBS containing 15% goat serum, 4% whey protein, and 0.5%
Tween-20. The supernatants (1:25–1:100 dilutions) were distrib-
uted to wells and incubated for 1 h at room temperature. In each
plate, affinity-purified human IgA, IgG, or IgM in the range of 0–
200 ng/ml (Jackson ImmunoResearch Laboratories) was included
for standard curves. After washing with PBS containing 0.1%
Tween-20, bound human IgA, IgG, and IgM were detected
separately with isotype-specific, horseradish peroxidase-labeled
goat anti-human immunoglobulins (Jackson ImmunoResearch
Laboratories) and the peroxidase substrate tetramethylbenzidine
(Kirkegaard and Perry Laboratories).
Tissue and Plasma Viral Load Determinations
Plasma HIV-1 RNA was measured by Roche Amplicor assay.
GALT samples obtained in the terminal ileum were flash frozen in
liquid nitrogen followed by pulverization and nucleic acid
extraction using the AllPrep DNA/RNA Mini Kit (Qiagen), as
described [29]. Sample RNA was treated with Turbo DNase
(Applied Biosystems) and proteinase K, extracted with phenol/
chloroform and precipitated with ethanol prior to generating
cDNA with the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). HIV copy number was determined by
quantitative PCR using a TaqMan probe labeled with FAM dye
(IDT) to a conserved region of the HIV gag gene against a serial
dilution of HIV gag cDNA synthesized from RNA transcribed
from the p59 plasmid (NIH AIDS Research and Reference
Reagent Program, catalog #3119) as described [30]. The limit of
detection for HIV-1 RNA is 20 copies/mg of total RNA. GAPD-
DH was assessed in duplex as an input control using a TaqMan
probe labeled with a CalFluor Orange 560 reporter (Biosearch
Technologies). Sequences for all primers and probes were
provided by S. Dandekar [29]. PCR products were analyzed with
Sequence Detection Software Version 1.3.1 (Applied Biosystems).
Plasma Antibody Levels
Plasma levels of IgM, IgG, and IgA antibodies specific for HIV-
1 gp41, gp120, gp140, and p55, as well as levels of rheumatoid
factor, were determined by ELISA as previously described [18,31].
Statistical Analysis
Statistical tests were performed in SAS v9.1 (SAS Institute). The
comparisons for terminal ileum and peripheral blood were
analyzed separately for each tissue type. In cases where there
were more than two groups, multiple degree of freedom F-tests for
groups were performed using PROC GLM in SAS v9.1, and
subsequent pairwise comparisons were made. For data consisting
of two groups only, t-tests using the Satterthwaite correction, two-
tailed Fisher’s exact tests, or two-tailed exact Wilcoxon tests were
performed using the appropriate SAS PROC test in SAS v9.1; the
statistical test used is noted when p-values are presented. Graphs of
the data were created using GraphPad Prism (GraphPad
Software).
Results
Effect of HIV-1 Infection on B Cells in Lamina Propria and
Peyer’s Patches of Terminal Ileum
First, immunohistologic analyses for apoptosis of B cells in
lamina propria areas were performed using TUNEL assays.
Apoptotic B cells were frequently seen in the lamina propria often
coincident with infiltration of CD68
+, CD11c
+ macrophages
(Figure 1A–1C).
The most striking changes were noted in the germinal centers of
Peyer’s patches (Table 3). Initial analysis of terminal ileum tissues
in AHI patients not on ART versus those on ART (mean duration
of therapy 31 d, Table 1) demonstrated no significant difference in
the degree of Peyer’s patch follicular lysis, characterized by follicle
damage, CD8
+ T cell and macrophage infiltration, and apoptosis
(94.7% in AHI patients not on ART versus 82.6% in AHI patients
on ART, Table 3). In terminal ileum tissues from AHI patients not
on ART, five of 19 (26.3%) follicles had a germinal center, and this
was not significantly different from tissues from AHI patients on
ART, in whom ten of 23 (43.4%) had discernable germinal
centers. Since similar B cell–inductive microenvironment damage
existed in AHI patients both on and not on ART, we combined all
HIV-1-Induced GALT Germinal Center Loss
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using immunohistology and flow cytometry data.
Overall, in seven terminal ileum tissue samples from uninfected
participants, only one of 32 germinal centers showed evidence of
follicle cell apoptosis outside of tingible body macrophages, and 21
of 32 (65.6%) B cell follicles contained germinal centers (Figure 2).
In contrast, out of 14 AHI patients’ tissues analyzed, only 15 of 42
(35.7%) B cell follicles contained germinal centers (p=0.018 for
AHI versus uninfected, Fisher’s exact test) (Figure 3).
In the Peyer’s patches of uninfected participants, TUNEL
+ cells
were rare, and when present, were phagocytosed by tingible body
macrophages within germinal centers (Figure 2B and 2E). In
contrast, in Peyer’s patches from AHI patients, TUNEL
+ cells were
abundant within the CD20
+ areas in 13 of 14 patients (Figures 4I,
S1B, and S3H). Even in the occasional B cell follicles that contained
relatively few TUNEL
+ B cells, other morphological evidence of
programmed cell death (apoptotic bodies, cells with nuclear
fragmentation) was clearly apparent either in the follicles or at the
follicular margins (Figures 4C, 5C, and 5D). The immunohistology
of most HIV-1
+ terminal ileal follicles was associated with TUNEL
+
Peyer’s patch follicular cells and loss of follicle architecture
(Figures 4I, 4O, S1, and S3C–S3H). Twelve of 14 (86%) AHI
patients had follicular areas with T cell apoptosis (Figure 4A–4F). In
10 of 14 AHI patients, B-cell follicles contained areas of both B and
T cell apoptosis (Figure 4G–4L), and all (14/14) AHI patients had
areas of either T cell or B cell apoptosis. When CD205
+, CD83
+,
and Langerin
+ dendritic cells were seen, they were either localized
in the submucosa below the epithelium (Figure S1A–S1H), or
within or around gut epithelium (Figure S2A–S2D).
FDC destruction over the course of HIV-1 infection has been
well documented, with initial FDC and germinal center hyper-
plasia followed by FDC destruction and germinal-center involu-
tion [32,33]. To determine how early these changes occurred after
HIV-1 infection, staining for FDCs was performed in 12 of 14
terminal ileum samples. We found that 53% of germinal centers
had evidence of FDC damage (Figure 6). In contrast, the FDC
network in five control tissue samples showed the fine reticular
pattern of normal FDCs using monoclonal antibodies to CD21,
CD35, and the low-affinity nerve growth factor receptor p75 [23]
(Figure 6A and 6E).
Zhang et al. have demonstrated SIV-induced B cell germinal
center loss in lymph nodes from rhesus macaques that were poor
antibody responders and were rapid progressors to AIDS; there
was a concomitant loss of Ki-67
+ germinal center B cells in
samples from these animals [34]. In the AHI participants in our
study, whether they were on ART or not, Ki-67
+ B cells were
frequently depleted (Figure 4M–4P), reflecting some degree of
germinal center disruption by HIV-1 in most patients studied.
When typical germinal centers were present in AHI gut, Ki-67
+
germinal center B cells were similarly present (Figure 3B).
Figure 1. Effect of HIV-1 on B cells in terminal ileum lamina propria. Lamina propria B cell apoptosis with CD11c
+ macrophage infiltration in
participant 015-5, 55 d after transmission, on ART 15 d. A cluster of lamina propria B cells (A; arrows), TUNEL stain of the same area with arrows
pointing out brown apoptotic nuclei (B), and the same area with infiltrating CD11c
+ macrophages (C) (1006).
doi:10.1371/journal.pmed.1000107.g001
Table 3. Germinal center damage in acute HIV-1 infection.
Group Patients Studied Total Follicles Studied Follicular Damage Present Follicles with Germinal Centers
AHI not on ART 6 19 18/19 (94.7%) 5/19 (26.3%)
AHI on ART
a 8 23 19/23 (82.6%) 10/23 (43.5%)
AHI total 14 42 37/42 (88.1%) 15/42 (35.7%)
Uninfected 7 32 1/32 (3.1%) 21/32 (65.6%)
p,0.0001
b p=0.018
b
aDuration of ART mean 31 d, range 14–63 d.
bTwo-tailed Fisher’s exact test for AHI total versus uninfected comparison.
doi:10.1371/journal.pmed.1000107.t003
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+ T Cells, CD11c
+
Macrophages, and Natural Killer Cells with Follicular B
Cell Apoptosis in Terminal Ileum of AHI Patients
In association with follicular B cell apoptosis, we found
infiltration of B cell follicles with CD11c
+, CD68
+ macrophages
(Figures 4F, 4L, S1C, and S3E), and CD8
+ T cells (Figures 4E, 4L,
4Q, and S3F), and loss of normal follicle architecture [35,36].
Overall, there were increased CD8
+ T cells and CD11c
+ myeloid
cell infiltrations in areas of apoptosis in 10 of 14 patients.
Activated natural killer (NK) cells are expanded in AHI, and
their cytolytic activity is correlated with the level of plasma
viremia, with a decrease in NK activity after the initiation of ART
[37]. While total NK cell numbers are expanded in AHI, there is
early depletion of CD56
hi CD16
2 NK cells that secrete cytokines
and chemokines [38]; continued viremia causes the remaining
cytolytic CD56
dim CD16
hi NK cells to become anergic. Thus,
activated NK cells could be a mediator of B cell death by direct
cytolysis or by antibody-dependent cellular cytotoxicity (ADCC),
and it was of interest to evaluate B cell follicles for CD16
+ and
CD56
+ NK cell infiltrations.
In tissues from uninfected participants, Peyer’s patches were
found to have CD16
+ NK cells intermixed with CD68
+ CD11c
+
macrophages and CD83
+ dendritic cells at the follicular dome just
under the site of follicle-associated epithelial cells (M cells)
specialized for antigen transport (Figure 2F) [39], consistent with
a recent report by Cella, et al. [40]. B cell areas with massive
Figure 2. Morphology of uninfected terminal ileum Peyer’s patch B cell–inductive microenvironments. Serial sections of the same
Peyer’s patch follicle in an uninfected terminal ileum (206). (A) CD20
+ B cells in a secondary follicle with germinal center (g). (B) The same follicle with
TUNEL staining showing that the predominant apoptotic cells are within tingible body macrophages (insert). (C) Ki-67
+ dividing B cells. (D) CD11c
+
follicular dendritic cells and macrophages. (E) CD68
+ macrophages and dendritic cells in the subepithelial zone below follicular associated epithelial
cells (arrow, top of photomicrograph) at the dome of the Peyer’s patch, and CD68
+ tingible body macrophages in the germinal center (insert). (F)
CD16
+ NK cells clustered in the areas below follicle associated epithelial cells (arrow).
doi:10.1371/journal.pmed.1000107.g002
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+, CD57
+ NK
cells [41], but did contain areas of infiltrations of CD56
+ NK cells
(Figures 5A–5D and S1F). Thus, while some degree of B cell
apoptosis may be mediated by NK cells, the majority is likely
mediated either directly or indirectly by CD8
+ T cells that were
consistently seen infiltrating apoptotic B cell areas (Figure 4Q).
CD16
+ as well as CD57
+ NK cells were scattered throughout the
lamina propria in similar patterns in both uninfected and infected
participants (unpublished data).
Effects of HIV-1 Infection on Numbers of Gastrointestinal
Tract Lamina Propria B Cells Using Quantitative Image
Analysis
We next evaluated the status of B cells in acute HIV-1 infection
in effector (lamina propria) areas in situ in terminal ileum using
immunohistochemistry. Figure 7A and Table S2 show the acute
HIV-1 induced changes in lamina propria B cell effector sites of
terminal ileum. In the lamina propria, there were significant
elevations of CD3
+ T cells (p=0.008) and CD8
+ T cells (p=0.003,
t-test) in AHI patients. Lamina propria CD4
+ T cells were
decreased in six of 12 biopsies compared to uninfected terminal
ileum biopsies (Table S2).
We studied lamina propria plasma cells for Ig isotype and k/l
light chain (LC) ratios to better understand plasma cell populations
during AHI. AHI patient number 003-7 had the highest number
of lamina propria IgG plasma cells and the second highest number
of IgA plasma cells, and had a k/l LC ratio of 1.7 (Table S2). AHI
patient number 025-7 had the highest number of IgA plasma cells
and a k/l LC ratio of 2.6; Figure 7C–7H show the lamina propria
profile of this participant (Table S2). Overall, after a mean of 82 d
after transmission the AHI terminal ileum group had an elevated
k/l LC ratio (1.6460.14) compared to uninfected terminal ileum
(k/l=1.1660.11; p=0.016, t-test) (Figure 7B). Similar k/l LC
skewing was observed in select Peyer’s patch follicles from AHI
patients (Figures S3A and S3B).
Effects of HIV-1 Infection on Percentages of
Gastrointestinal Tract B Cells Using Flow Cytometry
We next used flow cytometry to determine the percentages of
total terminal ileum B cells in tissues from AHI patients compared
to uninfected control tissues. In mononuclear cells, we found an
increase in the percentage of B cells in AHI terminal ileum (26.2%)
compared to control uninfected terminal ileum (12.5%) (p=0.006,
t-test). There were no differences between AHI patients who were
on or not on ART (25.3% versus 27.9%, respectively; mean
duration of therapy 31 d, range 14–63 d; Table 1). There was no
significant difference in naı ¨ve B cells between AHI and uninfected
participants (Figure 8A) but the percentages of gut memory B plus
plasmablasts/plasma cells (CD19
+ IgD
2 CD27
+) was elevated in
AHI versus uninfected participants (Figure 8B) (p=0.047, t-test).
Figure 3. Nearly normal morphology of secondary follicle in AHI terminal ileum. A near-normal terminal ileal secondary follicle in patient
018-4, 74 d after transmission, on ART 29 d (206). (A) CD20
+ B cells; (B) Ki-67
+ dividing germinal center B cells; (C) subepithelial CD3
+ T cells and a
small area of infiltrating CD3
+ T cells in the marginal zone around the germinal center (arrow); (D) normal-appearing CD11c
+ macrophages and
dendritic cells (arrow). TUNEL stain was negative for apoptotic nuclei (unpublished data).
doi:10.1371/journal.pmed.1000107.g003
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between AHI patients who were on or not on ART (unpublished
data).
Effect of HIV-1 on Peripheral Blood B Cell Subsets
We next used the same flow cytometric method to study B cell
subsets in peripheral blood in AHI versus uninfected participants.
The percentages and absolute numbers of total blood B cells in
AHI patients not on ART (n=12) versus AHI patients on ART
(n=9) were not different (4.0%, 195 B cells/ml versus 5.5%, 326 B
cells/ml, respectively). Similarly, no differences were seen in total
blood B cell absolute numbers/ml in AHI versus uninfected
participants (3.7%, 227 B cells/ml in uninfected participants)
(Table S3).
In contrast to reports of elevated numbers of blood naı ¨ve and
transitional B cells in the blood of patients with chronic HIV-1
infection [11–13], naı ¨ve B cells in the blood of patients with acute
and early HIV-1 infection were markedly decreased as a
percentage of the total B cell compartment (p=0.0001, t-test)
(Figure 8C). Calculated as absolute number of circulating naı ¨ve B
cells/ml of blood, we found no significant difference in naı ¨ve B cell
number between uninfected and AHI participants (Figure 8E).
The combined percentages and absolute numbers of memory B
cells and plasmablasts/plasma cells were elevated in the blood of
AHI patients (p=0.0003 and p=0.03, respectively, t-test)
(Figures 8D and 8F). Elevations of terminally differentiated B
cells in AHI were observed at the earliest time points studied, 17–
36 d after transmission, where the percentage of memory B and
plasma cells was 23.7%63.3% (range 12.4%–37.9%) compared to
9.4%61.9% in the uninfected control participants. Analyzed
separately, the percentages of both memory B cells and
plasmablasts/plasma cells in the blood of AHI patients were
elevated compared to uninfected control participants (p=0.005
and p=0.005, respectively, t-test) (Figure S4B and S4E). Absolute
number of circulating memory B cells were elevated in AHI
patients (p=0.01, t-test), whereas circulating plasmablasts/plasma
cells were similar to uninfected controls (Figure S4C and S4F).
Analysis was also performed for all of the B cell subsets
described above by separating participants into high plasma VL
and low VL groups. No significant differences were found for B
cell subsets between the two groups (t-test).
Recently, a population of CD19
+ IgM
+ CD27
+ B cells has been
described as IgM
+ memory B cells and/or circulating human
marginal zone B cells [42–44]. CD19
+ IgD
2 IgM
+ CD27
+ cells
were included in the above memory B cell analysis, but we did not
analyze the CD19
+ IgD
+ IgM
+ CD27
+ B cell subset. A separate
analysis of this population showed that the percentage of CD19
+
IgD
+ IgM
+ CD27
+ B cells in blood was similar in both uninfected
and AHI cohorts (7.0%61.5% in uninfected, 6.2%61.5% in
AHI, not significantly different, t-test). In terminal ileum, CD19
+
IgD
+ IgM
+ CD27
+ B cell percentages also were not different
between infected and uninfected participants (1.9%60.7% in
uninfected, 1.4%60.3% in infected, not significantly different, t-
test). Finally, including CD19
+ IgD
+ IgM
+ CD27
+ B cell
populations in our analyses did not alter our conclusion that
acute HIV-1 infection results in increased percentages of memory
cells in blood or gut (unpublished data).
EBV Transformation of Terminal Ileum Memory B Cells for
Analysis of Specificity of Antibodies Produced
EBV preferentially transforms recently primed B cells [45]. The
amount of IgM, IgG, or IgA produced in 96-well cultures of EBV-
transformed B cells was determined in six AHI terminal ileum
samples versus terminal ileum from six uninfected participants. If
Figure 4. Stages of B cell apoptosis in terminal ileal Peyer’s patches soon after HIV-1 transmission. (A–F) Early follicular lysis in a primary
follicle of patient 019-2, 47 d after transmission, not on ART; arrows in each photomicrograph show same mantle zone T cell area (A–P, 406). (A)
Hematoxylin and eosin stain. (B) CD20. (C) TUNEL stain with apoptosis in the mantle zone. (D) Rim of CD4
+ T cells in apoptotic mantle zone. (E)
Infiltrating CD8
+ T cells. (F) Infiltrating CD11c
+ macrophages. (G–P) Serial sections of a small germinal center remnant in patient 023-3, 66 d after
transmission, not on ART (plasma viral load 203 copies/ml, and the only participant in this study who spontaneously controlled plasma viremia). (G)
Hematoxylin and eosin stain. (H) CD20
+ B cells. (I) TUNEL stain of apoptotic B cells surrounding a small germinal center. (J) Follicular CD4
+ depletion
with weakly stained CD4
+ macrophages. (K) CD8
+ T cells in follicle areas around the germinal center. (L) CD68
+ tingible body macrophages in the
germinal center (arrows). (M) Ki-67
+ dividing germinal center cells in serial sections with same area outlined in dotted line; (N) CD20
+ B cells in same
area. (O) TUNEL-stained apoptotic cells surrounding the Ki-67
+, nonapoptotic germinal center B cells. (P) CD11c
+ myeloid cells. (Q) Brown CD8
+ T cells
in close apposition to apoptotic and fragmented cells (arrows) in patient 017-9, 56 d after transmission and not on ART (1006).
doi:10.1371/journal.pmed.1000107.g004
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increased number of primary EBV-transformed cultures produc-
ing supernatant IgG and IgA after EBV transformation compared
to terminal ileum B cell cultures from uninfected individuals. In
addition, if there are more primed IgM
+ B cells present in terminal
ileum, there should be more B cell cultures with elevated IgM.
Figure 9 shows that this was the case with more IgM-, IgG-, and
IgA-producing B cell cultures in AHI terminal ileum 2 wk after
EBV stimulation versus uninfected EBV-transformed B cell
cultures.
Next, we determined the relative frequency of the specificities of
antibodies in each EBV-transformed well of B cells to determine
the relative percentages of B cells responding to HIV-1, either as
HIV-1–specific or as polyclonally induced antibodies (Table 4).
This method of analysis does not reflect the absolute percentage of
memory B cells making various antibody specificities, because the
gut mononuclear cells were cultured at 10,000 cells per well as
opposed to single cell per well cultures. Rather this analysis
provides the relative frequency of antibody specificities in the
entire terminal ileum memory B cell population. In uninfected
participants, 8/420 (1.9%) of EBV-transformed B cell cultures
were positive for gp41 antibodies, and 1.9% were positive for
gp120 antibodies (IgM only); none were positive for antibodies to
HIV-1 Tat, while 1.4% and 0.2% were positive for anti-
cardiolipin antibodies or rheumatoid factor, respectively
(Table 4). Two percent of cultures from uninfected participants
were also positive for reactivity with the 2007 inactivated influenza
vaccine Fluzone (Sanofi Pasteur). In contrast, in AHI terminal
ileum, 18.6% of EBV B cell cultures were positive for antibodies to
HIV-1 gp41, 5.7% for antibodies to HIV-1 gp120, and 9.3% for
antibodies to HIV-1 Tat. In addition, 6.2% of AHI B cell cultures
were reactive with cardiolipin, 3.0% had rheumatoid factor
activity and 16.2% were reactive with the 2007 inactivated
influenza vaccine (Table 4). Taken together this pattern of relative
specificities of EBV-transformed memory B cells indicated the
presence of a large component of polyclonal B cell activation in
addition to HIV-1–induced specific antibody responses.
Relationship of Plasma and GALT HIV-1 Viral Load to
Peyer’s Patch Germinal Center Morphology
We identified Peyer’s patch follicles containing germinal centers
at various stages of damage in eight AHI patients (Figure 3A–3D;
Table 1). Comparison of GALT germinal center depletion and
plasma VL demonstrated that those with germinal center
depletion had significantly higher viral loads (mean 34,065
copies/ml) than those with germinal centers (mean 1,711
copies/ml) (p=0.021, exact Wilcoxon test). Six of eight patients
with germinal centers had initiated ART, while only two of six of
the patients with no germinal centers were on ART. These data
are in contrast to the work of Muro-Cacho et al. who showed that
the intensity of lymph node apoptosis in advanced HIV-1 infection
did not correlate with plasma VL [46]. It is of interest that, of the
Figure 5. Infiltration of NK cells in apoptotic and nonapoptotic areas of AHI terminal ileum Peyer’s patches of patient 018-4. (A and
B) The same follicle with germinal center as in Figures 3A–3D; brown CD16
+ cells (A) and CD56
+ cells (B). These photomicrographs show normal
accumulation of NK cells in subepithelial areas. (C and D) An apoptotic Peyer’s patch area in patient 018-4 terminal ileum with brown CD16
+ cells (C),
and CD56
+ cells (D). In all four panels arrows indicate positive cells (406).
doi:10.1371/journal.pmed.1000107.g005
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controlled plasma viremia in the absence of ART (203 copies/ml
at the time of sampling 66 d after transmission) also had some
degree of germinal center preservation (Figure 4G–4P). GALT-
associated HIV-1 RNA did not correlate with germinal center
depletion (Table 5) [47].
Effect of Presence of Peyer’s Patch Germinal Centers and
Antiretroviral Treatment During Acute HIV-1 Infection on
Plasma Rheumatoid Factor Levels and HIV-1 Protein
Antibody Levels
Comparison of HIV-1 envelope and gag p55 antibodies in
patients with germinal centers to those with no germinal centers
showed no differences except for higher anti-gp41 IgG antibodies
in those without germinal centers (p=0.005, t-test) (Table 6).
Similarly, there was no difference in antibody levels when the
participants providing terminal ileum biopsies (Table 1) were
grouped as high- (.20,000 copies/ml) versus low plasma VL
(,20,000 copies/ml) (unpublished data). We next determined the
effect of early institution of ART on levels of plasma IgM, IgG and
IgA antibodies against HIV-1 gp41, p55, gp120 and gp140, as well
as plasma rheumatoid factor levels, in patients from whom
terminal ileal biopsies were obtained (Table 7). The time from
transmission in the treated versus the non-treated group was
similar (82 d versus 79 d) (Table 1). As expected, the anti-gp41
IgA, anti-gp140 IgA, and anti-gp140 IgG levels were significantly
lower in the AHI on ART group compared to the AHI on no
ART group. Thus, even one month of ART significantly lowered
plasma levels of antibody to HIV-1 Env following HIV
transmission.
Discussion
By as early as 17 d after transmission, HIV-1 infection induced
B cell class switching manifested by acute reductions in numbers of
naı ¨ve B cells and striking elevations of memory B cells and
plasmablasts/plasma cells in blood and terminal ileum. By 47 d
after transmission, HIV-1 infection was associated with damage to
GALT germinal centers, including follicular lysis due to B and T
cell apoptosis as well as destruction of the FDC networks in
terminal ileum Peyer’s patches.
HIV-1-Induced Polyclonal B Cell Activation
In this study we document, to our knowledge for the first time,
polyclonal B cell activation in terminal ileum in early HIV-1
infection. HIV-1–induced polyclonal B cell activation has been
well documented in chronic HIV-1 infection, and several studies
have used assays to characterize unstimulated (or spontaneous)
secretion of anti-HIV-1 antibody by circulating B cells during the
Figure 6. Changes in FDCs) in AHI. (A–D) 206; (E–H) 406. (A and E) The fine reticular network of FDCs in an uninfected terminal ileum Peyer’s
patch (stained with p75 nerve growth factor receptor monoclonal antibody NGFR5). (B and F) Typical hyperplastic FDCs in patient 018-4, 74 d after
transmission (stained with NGFR5 monoclonal antibody). (C) (stained with CD21 monoclonal antibody 1F8) and (G) (stained with CD35 monoclonal
antibody BerMAC) show condensation and early loss of FDC in AHI terminal ileum 010-1, 52 d after transmission. (D) (stained with NGFR5 monoclonal
antibody) and (H) (stained with CD35 monoclonal antibody BerMAC) show progressive FDC destruction in terminal ileum 025-7, 105 d after
transmission.
doi:10.1371/journal.pmed.1000107.g006
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PLoS Medicine | www.plosmedicine.org 11 July 2009 | Volume 6 | Issue 7 | e1000107Figure 7. Effect of HIV-1 on Terminal Ileum Immune Cells. (A–B) Bars (A) and horizontal line (B) show mean values; error bars show standard
error of the mean. (A) Quantitative image analysis of terminal ileum lamina propria immune cells in six uninfected participants, six AHI patients not on
ART, and eight AHI patients on ART. CD3
+ T cells were elevated in AHI (*p=0.008, t-test) as were CD8+ T cells (
{p=0.003, t-test). (B) Lamina propria k/
l ratio skewing (p=0.016, t-test). (C–H) (1006) Lamina propria of patient 025-7, 105 d after transmission, on ART 63 d, with predominant IgA, k
plasma cell expansion (k/l ratio=2.53). (C) IgM, (D) IgG, (E) IgA, (F) Hematoxylin and Eosin stain, (G) k light chains, and (H) l light chains.
doi:10.1371/journal.pmed.1000107.g007
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Figure 8. Flow cytometric analysis of B cell populations. For all analyses, B cells were identified as CD3
2 CD14
2 CD16
2 CD235a
2 and CD19
+.
Horizontal lines show mean values; error bars show standard error of the mean. (A) Terminal ileal naı ¨ve B cell percentages. Naı ¨ve B cells were defined
as B cells that were also surface IgD
+ and CD27
2. In cells from terminal ileal biopsies, uninfected participants had a mean6standard error of the mean
29.9%67.0% of naı ¨ve B cells that were decreased to 15.7%68.9% in AHI patients. (B) Terminal ileal memory and plasma cell percentages. Memory B
and plasma cells were defined as B cells that were also surface IgD
2 and CD27
+, leaving out IgD
+ IgM
+ CD27
+ B cells. In terminal ileum, uninfected
participants had 17.1%65.8% of memory B and plasma cells that were increased to 36.4%66.9% in AHI patients (p=0.047, t-test). (C) Peripheral
blood naı ¨ve B cell percentages. Uninfected participants had 71.1%62.9% of naı ¨ve B cells that were decreased to 49.7%64.2% in AHI patients
(p=0.0001, t-test). (D) Peripheral blood IgD
2 CD27
+ memory and plasma cell percentages. Uninfected individuals had 9.4%61.9% of memory B and
plasma cells that were increased to 20.2%62.6% in AHI patients (p=0.0003, t-test). (E) Absolute numbers of circulating peripheral blood naı ¨ve B cells.
Calculated as absolute naı ¨ve B cells per microliter of blood, uninfected participants had 169623 cells/ml, while AHI patients had 148648 cells/ml. (F)
Absolute circulating memory B and plasma cells. Calculated as absolute number of cells per microliter of blood, uninfected individuals had 21.664.4
cells/ml, and 36.064.4 cells/ml in AHI participants (p=0.03, t-test). All data in this figure were also analyzed using a two-tailed exact Wilcoxon test that
resulted in similar p-values.
doi:10.1371/journal.pmed.1000107.g008
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al. reported increased frequencies of B cells that (spontaneously)
secreted Ig in blood of patients chronically infected with HIV-1,
and also demonstrated elevated levels of B cells that (spontane-
ously) produced specific antibody to gp120 [14]. The same group
also assayed blood from three patients recently infected with HIV-
1 and found elevated numbers of antibody-secreting cells specific
for Env gp120 [14]. The mechanism of HIV-1 gp120-induced
polyclonal B cell activation in chronic HIV-1 infection may be
mediated by cytokines such as IL-15 and TNF-a [49,50], by
translocation of bacteria and lipopolysaccharide across gut barriers
[51], by gp120 binding as a superantigen to VH3 Ig
+ B cells [52],
and/or gp120 binding to mannose C-type lectin receptors on a
subset of B cells [53]. Whether these mechanisms of B cell
activation are operative in early HIV-1 infection remains to be
determined.
Follicular Damage and Germinal Center Loss in HIV-1
Infection
The germinal center loss seen in terminal ileum may be more
pronounced early on after infection than has been previously
reported in lymph nodes and spleen, where germinal center
hyperplasia is common in AHI [54,55]. Germinal center
hyperplasia was seen in our study in AHI terminal ileum, but
significant germinal center destruction was also present that
correlated with plasma viral load. One difference may relate to the
massive and early CD4
+ T cell loss that is so prominent in gut
tissues [1–5]. The early loss of gut B cell germinal centers may
impair effective humoral responses to HIV-1. CD4
+ T cell help is
required for induction of long-lived plasma cells and long-term
production of high-affinity antiviral antibodies [56]. Thus, given
early damage and/or loss of GALT follicles with germinal centers,
one expectation would be that the apparent half-life of induced
antibody to HIV-1 would be short (weeks to months) and not
reflect a level maintained by long-lived plasma cells (,10 y or
longer) [57]. This hypothesis is indeed consistent with the reported
apparent half-life of anti-p24 and anti-gp120 antibodies in
chronically infected patients of 9–15 wk and 7–21 wk, respectively
[14]. The destruction of germinal centers due to inflammation and
the lack of production of neutralizing antibodies have also been
reported for another model of chronic viral infection, lymphocytic
choriomeningitis virus, where chronic CD27-mediated stimulation
of T cells by CD70 on B cells resulted in cytokine-mediated
germinal center destruction [58]. It will be of interest in future
studies to determine if this mechanism is responsible for the
destruction seen in acute HIV-1 infection in humans.
Pauza and colleagues demonstrated loss of peripheral B cells in
monkeys with acute SIV infection that rapidly progressed to AIDS
in the absence of seroconversion [59,60], and Zhang et al. have
recently demonstrated loss of germinal centers in three additional
SIV
+ rhesus macaques that progressed rapidly to AIDS [34]. A
previous study of B cells in patients with primary HIV-1 infection
showed decreases in total peripheral blood B cell levels by 2 mo
after transmission [15]. That study went on to show elevated levels
of apoptotic naı ¨ve B cells in early HIV-1 infection, with levels of
naı ¨ve and memory B cells similar to infected controls. Our study
demonstrated no significant difference in blood total B cell
numbers in acute HIV-1 infection (Table S3) and striking
elevations in memory and plasma cells not seen in prior work.
These findings are likely due to the short time since HIV-1
infection of participants in the present study.
Follicular lysis of mantle zones of lymph node follicles in chronic
HIV-1 infection, first described in 1985, consists of destruction of
FDCs in germinal centers, loss of germinal center morphology,
and germinal center infiltration with CD8
+ T cells and
macrophages [35,36]. Early studies described an increase in
lymph node CD1
+ Langerhans dendritic cells in the paracortex of
chronic HIV-1 lymph nodes [35,36]. In contrast, in AHI in
Peyer’s patches and lamina propria of terminal ileum, we saw no
increase in CD83
+ or Langerin
+ dendritic cells, but saw striking
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Figure 9. Total immunoglobulin (Ig) levels and specificities in
the EBV-transformed B cell cultures. Horizontal lines show mean
values; error bars show standard error of the mean. Graph shows the
levels of IgA, IgG, and IgM in the cell culture supernatants derived from
terminal ileal samples of six acute/early HIV-infected and six uninfected
participants determined by ELISA 14 d after EBV transformation. Each
data point represents the geometric mean of IgA, IgG, and IgM levels in
all wells plated from each terminal ileum sample.
doi:10.1371/journal.pmed.1000107.g009
Table 4. Percentage of EB virus-stimulated cultures producing antibodies reactive with HIV and non-HIV antigens.
Group Antibody Specificity
gp41 p120 Tat Cardiolipin Rheumatoid Factor Fluzone
Acute/Early HIV
Infection (n=8)
18.6% (108/580) 5.7% (17/296) 9.3% (37/396) 6.2% (22/353) 3.0% (9/296) 16.2% (22/136)
Uninfected (n=4) 1.9% (8/420) 1.9% (8/420) 0% (0/420) 1.4% (6/420) 0.2% (1/420) 2.1% (9/420)
Fisher’s exact test p,0.0001 p=0.007 p,0.0001 p=0.0004 p=0.0021 p,0.0001
Table shows the percentage of wells of terminal ileum cells seeded at 10
4 cells/well and assayed 21–28 d after EBV transformation. Percentages represent positive wells
out of number of cultures indicated that were assayed for antibodies reactive with gp41, gp120, Tat, CL, and killed influenza in the 2007 influenza vaccine Fluzone, as
well as RF. The comparison group was a total of 420 cultures from four uninfected participants.
doi:10.1371/journal.pmed.1000107.t004
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+ T
cells and CD11c
+ CD68
+ macrophages.
Mechanisms of Damage to Terminal Ileum Inductive
Microenvironments
The mechanisms of terminal ileum Peyer’s patch B cell
apoptosis in AHI are yet to be fully determined. However,
CD8
+ T cell infiltration has been well documented in HIV-1
lymph nodes [54] and thymus [61], and lymph node CD8
+ T cells
are armed for effector formation [62]. The close association of
CD8
+ T cells with apoptotic cells in B cell areas (Figure 4Q),
accompanied by increased numbers of CD8
+ T cells in blood and
terminal ileal biopsies from patients who exhibit extensive
germinal center loss (Table 4) suggests CD8-mediated B cell
killing. The infiltration of CD11c
+ CD68
+ macrophages into
apoptotic B cell areas may represent the clearing of apoptotic cells
and cell debris by phagocytosis, or, alternatively, activation of
macrophage-dependent cytotoxicity such as ADCC. From the
patterns of CD16
+ CD57
+ NK effector cells seen infiltrating
lymphoid follicles, NK cells as predominant effectors of killing of
follicle B cells seems unlikely. B cell apoptosis could also result
from changes in positioning cues, e.g., inflammatory or homeo-
static cytokines, caused by infection and/or the apoptotic process
per se. We have previously shown early elevations in plasma tumor
necrosis factor apoptosis-inducing ligand (TRAIL) in AHI before
peak viral load, and B cell death within germinal centers could
reflect TRAIL-mediated bystander B cell killing [63]. Fas ligand
and tumor necrosis receptor type II (TNFRII) plasma levels are
also elevated soon after TRAIL in AHI [63] as are plasma TNF-a
levels [64]—all of which could contribute to B cell death. That B
cell apoptosis is localized to B cell areas surrounding germinal
centers and where HIV-1 is localized [47,65] also suggests that
HIV-1 may trigger B cells to activation-induced cell death after
antigen presentation by follicular dendritic cells.
Table 5. Comparison of AHI patients with terminal ileum germinal centers versus those without terminal ileum germinal centers.
Parameter With Terminal Ileum Germinal Centers
a Without Terminal Ileum Germinal Centers
Number of patients 8 6
Plasma viral load (RNA copies/ml, mean
b [range]) 1,711 (,50–387,344)
c 34,065 (6,570–123,928)
c
GALT viral load (RNA copies/ml, mean
b [range]) 324 (,50–10,639) 449 (38–44,816)
CD4 cells in PBMC (cells/ml) 735 609
CD4 cells in tissue (cells/mm
3) 49,708 31,648
CD8 cells in PBMC (cells/ml) 1,174 1,046
CD8 cells in tissue (cells/mm
3) 184,162 201,564
Estimated time from transmission, d 80 81
Patients on ART 6/8 2/6
Days on ART prior to biopsy 36 d 16 d
k/l LC ratio 1.63 1.65
aPatients 019-2, 023-3, 008-6, 010-1, 016-8, 018-4, 025-7, 016-2 from Table 1.
bPlasma viral load and GALT viral load are calculated as geometric means.
cp=0.021, exact Wilcoxon test, comparing patients with terminal ileum germinal centers versus those without terminal ileum germinal centers.
doi:10.1371/journal.pmed.1000107.t005
Table 6. Antibody responses to HIV-1 proteins: Antibody to
HIV-1 proteins in AHI with germinal centers versus no
germinal centers.
Group Antibody Specificity (mg/ml Equivalent)
gp41 p55 gp120 gp140
Rheumatoid
Factor
AHI with terminal ileum germinal centers (n=8)
IgM 3.8 3.6 0.6 0.1 0.3
IgG 22.0
a 30.2 3.7 1.5 N/A
IgA 2.9 2.1 1.2 1.0 N/A
AHI without terminal ileum germinal centers (n=6)
IgM 1.1 6.3 1.4 0.5 0.5
IgG 39.6* 40.1 6.7 7.1 N/A
IgA 4.1 3.4 1.2 1.2 N/A
agp41 antibodies are higher for patients without germinal centers (t=3.62,
p=0.005) by unequal variance t-test.
N/A, not applicable.
doi:10.1371/journal.pmed.1000107.t006
Table 7. Effect of antiretroviral treatment in AHI on HIV-1
antibody responses.
Group Antibody Specificity (mg/ml Equivalent)
gp41 p55 gp120 gp140
Rheumatoid
Factor
AHI not on ART (n=6)
IgM 1.7 6.4 0.5 0.8 0.5
IgG 36.0 29.7 5.7 7.1
a N/A
IgA 5.4
b 2.3 1.2 1.7
c N/A
AHI on ART (n=8)
IgM 3.4 3.5 1.1 1.0 0.4
IgG 24.8 38.1 4.4 1.5
a N/A
IgA 1.9
b 2.9 1.2 0.6
c N/A
Responses lower in AHI on ART group versus AHI not on ART group by unequal
variance t-test (
aIgG gp140, p=0.047;
bIgA gp41, p=0.020;
cIgA gp140,
p=0.020).
N/A, not applicable.
doi:10.1371/journal.pmed.1000107.t007
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populations of B cells that soon require T cell help for their
continued survival [66–70], help that is unavailable because
antigen-specific T helper cells are not present or have been lost to
infection and cell lysis. In the absence of cognate T cell help, B
cells generally die within a few days of their activation [66–70].
This physiologic requirement for the interaction of antigen-specific
T- and B lymphocytes ensures that under physiologic conditions
long-lived B cells, memory B cells, and plasma cells resident in
bone marrow are regulated by the stringent mechanisms that
control T cell tolerance [71,72]. This model can explain the rapid
follicular lysis and losses of naı ¨ve B cells associated with acute
HIV-1 infection.
Given the ability of HIV-1 to induce polyclonal B cell
activation, our observation of skewed k/l LC ratios in GALT
tissue from AHI patients is intriguing. We have recently sorted and
sequenced Ig genes from a total of over 700 plasmablasts/plasma
cells from blood of three AHI patients. In these individuals, the k/
l LC ratios were similarly elevated as assayed by direct Ig
sequencing of sorted plasmablasts/plasma cells (unpublished data).
Interestingly, similar k/l LC ratio skewing has been reported in
responses to gp120 in SIV-infected rhesus macaques [73], and in
the response to HIV-1 gp120, p24, and reverse transcriptase in
HIV-1 infection in humans [74].
There are several limitations to our study that warrant further
work. First, of necessity we obtained the terminal ileum biopsies
from limited areas and they may not be fully representative of all
gut areas. Additional work may reveal a more detailed picture of
early HIV-1–induced immune system damage. EBV transforma-
tion of memory B cells can skew the B cell repertoire, such that our
comparison of uninfected and AHI participants is only qualitative.
Finally, heterogeneity of patient responses to both HIV-1 infection
and ART can confound data analysis. These issues not
withstanding, the damage to B cell–inductive microenvironments
and early polyclonal B cell differentiation in HIV-1 infection are
apparent from the present analyses.
Conclusion
Early HIV-1 infection induces germinal center damage and loss
as well as polyclonal activation of gut B cells. These data suggest
that for an HIV-1 vaccine to be effective, it will need to induce
significant levels of broadly neutralizing antibodies that are present
before HIV-1 transmission. If transmission is not prevented by
preexisting antibody, then an effective AIDS vaccine will also need
to prime for rapid (hours to days) innate responses of anti-HIV-1
factors (such as defensins [75], alpha-1-antitrypsin [76], CCR5
binding chemokines [77], or anti-HIV-1 NK cell responses
[78,79]) that might protect against HIV-1–induced follicular
germinal center B cell and CD4
+ T cell loss until robust CD8
+ T
cell and secondary B cell responses are induced.
Supporting Information
Figure S1 Subepithelial remnant of a B cell germinal center in
patient 023-3, 66 d after transmission, not on ART showing a rare
cluster of CD83
+ and CD205
+ dendritic cells. (A) CD20
+ B cells;
(B) TUNEL
+ apoptotic cells; (C) CD11c
+ infiltrating macrophages;
(D) few of the CD11c
+ cells are CD83
+ dendritic cells (arrow); (E)
scattered CD205
+ dendritic cells (arrows); (F) scattered CD16
+ NK
cells (arrow); (G) scattered CD57
+ cells (arrow); (H) rare Ki-67
+
cells (arrow) (406).
Found at: doi:10.1371/journal.pmed.1000107.s001 (4.7 MB TIF)
Figure S2 Langerin
+ dendritic cells, when present, were
associated with epithelial cells. (A–D) Patient 023-3 66 d after
transmission not on ART. Arrows show Langerin
+ dendritic cells
in and around epithelial cells of terminal ileum villi (1006).
Found at: doi:10.1371/journal.pmed.1000107.s002 (4.6 MB
TIF)
Figure S3 Ig light chain staining of Peyer’s patch in patient 008-
6 and extensive B cell destruction in patient 020-4. (A and B)
Kappa light chain predominance in a Peyer’s patch follicle in
patient 008-6, 67 d after transmission, on ART 17 d. Figure S4A
shows a follicle area with brown kappa positive cells in center of
tissue, with the same area in the sequential section (B) with fewer
lambda light chain B cells present (106). (D–H) Extensive B cell
destruction in serial Peyer’s patch areas of patient 020-4, 113 d
after transmission, not on ART. (C) CD20
+ B cells; (D) scattered
Ki-67
+ cells (arrows); (E) mass of CD11c
+ macrophages in the
same area; (F) CD8
+ T cells infiltrating apoptotic area; (G)
scattered CD16
+ NK cells; (H) TUNEL stain showing cells with
apoptotic nuclei in brown (406).
Found at: doi:10.1371/journal.pmed.1000107.s003 (7.3 MB
TIF)
Figure S4 Flow cytometric analysis of B cell populations. As in
Figure 1, for all analyses, B cells were identified as CD3
2
CD14
2 CD16
2 CD235a
2 and CD19
+. (A) Terminal ileal
memory B cell percentages. Memory B cells were defined as B
cells that were also surface IgD
2, CD38
2/+, and CD27
+. In cells
from terminal ileal biopsies uninfected participants had
12.9%65.4% of memory B cells that were increased to
26.8%65.4% in AHI patients. (B) Peripheral blood memory B
cell percentages. Uninfected participants had 7.3%61.4% of
memory B cells that were increased to 13.1%61.6% in AHI
patients (p=0.005). (C) Absolute numbers of circulating memory
B cells. Calculated as absolute memory B cells per microliter of
blood, uninfected participants had 15.462.0 cells/ml that were
increased to 27.063.7 cells/ml in AHI patients (p=0.01). (D)
Terminal ileal plasma cell percentages. Plasma cells were defined
as B cells that were also surface IgD
2, CD38
hi, and CD27
+.I n
terminal ileum, uninfected participants had 4.2%61.5% of
plasma cells that were increased to 9.6%63.2% in AHI patients.
(E) Peripheral blood plasma cell percentages. Uninfected
participants had 2.1%60.8% of circulating plasma cells that
were increased to 7.1%61.9% in AHI patients (p=0.005). (F)
Absolute circulating plasma cells. Uninfected participants had
circulating plasma cells at 6.263.1 cells/ml while AHI patients
had 9.061.8 cells/ml. Absolute cell number data (Figure S4C
and S4F) were also analyzed using a two-tailed exact Wilcoxon
test resulting in similar p-values.
Found at: doi:10.1371/journal.pmed.1000107.s004 (0.52 MB
EPS)
Table S1 Antibodies and their source used in immunohistologic
analysis.
Found at: doi:10.1371/journal.pmed.1000107.s005 (0.06 MB
DOC)
Table S2 Terminal ileal biopsy histologic data.
Found at: doi:10.1371/journal.pmed.1000107.s006 (0.1 MB
DOC)
Table S3 Total B cell populations in blood in acute HIV-1
infection.
Found at: doi:10.1371/journal.pmed.1000107.s007 (0.04 MB
DOC)
Text S1 Additional methods.
Found at: doi:10.1371/journal.pmed.1000107.s008 (0.04 MB
DOC)
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Background. Acquired immunodeficiency syndrome (AIDS)
has killed more than 25 million people since 1981 and more
than 30 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV infects
and kills a type of immune system cell called CD4
+ T
lymphocytes. These cells are needed to maintain a vigorous
immune response, so people infected with HIV eventually
become susceptible to other infections and develop full-
blown AIDS. However, early during HIV infection, other parts
of the immune system attempt to fight off the virus. Soon
after infection, immune system cells called B lymphocytes
begin to produce HIV-specific antibodies (proteins that
recognize viral molecules called antigens). The first
antibodies to HIV usually appear two to seven weeks after
infection; from about 12 weeks after infection, antibodies are
made that can kill the specific HIV type responsible for the
infection (neutralizing antibodies).
Why Was This Study Done? Unfortunately, by this time, it
is too late for the antibody (‘‘humoral’’) immune response to
clear HIV from the body. Indeed, the humoral immune
response to HIV is very slow; for most viruses, neutralizing
antibodies appear within days of infection. To help them
design an effective HIV vaccine, scientists need to
understand how the virus delays humoral responses to HIV
infection (and how it later causes the production of HIV-
specific antibodies to decline). Little is known, however,
about the early effects of HIV infection on B lymphocytes.
These cells are born and mature in the bone marrow. ‘‘Naı ¨ve’’
B lymphocytes, each of which carries an antigen-specific
receptor (a protein that binds to a specific antigen), then
enter the blood and circulate around the body, passing
through the ‘‘peripheral lymphoid organs’’. Exposure to
antigens in these organs, which include lymph nodes and
gut-associated lymphoid tissues, activates the subset of B
lymphocytes that recognize the specific antigens that are
present. Finally, with the help of activated T lymphocytes,
the activated B lymphocytes proliferate and change
(differentiate) into antibody-secreting cells and memory B
lymphocytes (which respond more quickly to antigen than
naı ¨ve B lymphocytes). In this study, the researchers
investigate the effects of early HIV-1 infection on B
lymphocytes in blood and in gut-associated lymphoid
tissues.
What Did the Researchers Do and Find? The researchers
collected blood from patients as early as 17 days after HIV-1
infection and tissue samples from the lower portion of the
small intestine (a region rich in gut-associated lymphoid
structures called Peyer’s patches) from 47 days after infection
onward. When they analyzed the B lymphocytes in these
samples (which were collected during two trials organized
by the US Center for HIV/AIDS Vaccine Immunology [CHAVI]),
they found that HIV-1 infection rapidly induced the
activation of many different B cells that recognized a
variety of antigens (polyclonal activation), as well as the
appearance of differentiated B cells in blood and in gut-
associated lymphoid tissue. The B lymphocytes that were
activated in the gut made HIV-specific antibodies but also
antibodies against unrelated antigens (such as flu virus
proteins). Finally, the structure of Peyer’s patches was altered
early in HIV-1 infection. More specifically, most of the
lymphoid follicles (organized collections of lymphocytes
and antigen-presenting cells) in the Peyer’s patches showed
signs of damage and T- and B-lymphocyte death and the
number of germinal centers (regions in lymphoid follicles in
which B lymphocytes proliferate) was reduced.
What Do These Findings Mean? Although the depletion
of gut-associated CD4+ T lymphocytes in early HIV-1
infection is well known, these new results demonstrate the
effects of early HIV-1 infection on gut-associated and
circulating B lymphocytes. The results of this study are
limited by the methods used to analyze the antibodies
induced by HIV infection and by only taking tissue samples
from one region of the gut. Nevertheless, the findings of
polyclonal B-cell activation and damage to gut-associated
lymphoid follicles soon after HIV-1 infection may have
implications for HIV-1 vaccine design. Specifically, these
findings suggest that an effective HIV-1 vaccine will need to
ensure that significant levels of neutralizing antibodies are
present in people before HIV-1 infection and that other
protective immune defenses are fully primed so that, in the
event of HIV-1 infection, the virus can be dealt with
effectively before it disables any part of the immune system.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000107.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including an article about how HIV-1 infection
affects the immune system
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the stages of HIV infection, and on AIDS vaccines
(in English and Spanish)
N The US Center for HIV/AIDS Vaccine Immunology (CHAVI)
Web site provides information on research designed to
solve major problems in HIV vaccine development and
design
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